Autologous Stem Cell Rescue for Primary Amyloidosis

NCT00186407 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-09-14

No results posted yet for this study

Summary

To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.

Conditions

  • Amyloidosis
  • Blood and Marrow Transplant (BMT)

Interventions

PROCEDURE

high dose chemo then auto hematopoietic cell transplant

Sponsors & Collaborators

Principal Investigators

  • Sally Arai · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2008-02-29
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186407 on ClinicalTrials.gov